Product Description
Barusiban is an oxytocin antagonist under development for potential use as tocolytic in preterm-labor patients. Barusiban (FE 200440) is a peptide oxytocin antagonist for potential future use as a tocolytic drug in preterm-labor patients, being slightly smaller than atosiban. (Sourced from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7313255/)
Mechanisms of Action: OXTR Antagonist
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Ferring
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Infertility|Pregnancy Outcomes|Other|Infertility, Male|Infertility, Female|Obstetric Labor, Premature